Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Dirk, Strumberg,; Jeffrey W, Clark,; Ahmad, Awada,; Malcolm J, Moore,; Heike, Richly,; Alain, Hendlisz,; Hal W, Hirte,; Joseph P, Eder,; Heinz-Josef, Lenz,; Brian, Schwartz,

doi:10.1634/theoncologist.12-4-426

Public

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Published in The oncologist • Apr 1, 2007

Authors:

Strumberg, Dirk

Clark, Jeffrey W

Awada, Ahmad

Abstract

Sorafenib is an oral multikinase inhibitor that inhibits Raf serine/threonine kinases and receptor tyrosine kinases involved in tumor growth and angiogenesis. It has demonstrated preclinical and clinical activity in several tumor types. Sorafenib 400 mg twice daily (bid) has been approved in several...

Subject

Antineoplastic Agents

Benzenesulfonates

Clinical Trials

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!